Metabolic Reprogramming in Toll-like Receptor-Mediated Platelet Activation
Cells · 2025
DOI: 10.3390/cells14120906 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Lih T Cheah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Discovery and Translational Science Department, Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds LS2 9JT, UK. Hauptthemen laut MEDLINE: Platelet Activation, Blood Platelets, Toll-Like Receptors, Toll-Like Receptor 2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation.
Abstract (Originalsprache)
Beyond haemostasis and thrombosis, platelets are increasingly recognized for playing a crucial role in modulating immunoinflammation. Toll-like receptors (TLRs) constitute the first line of defence against infection and injury, with their engagement stimulating thrombotic and immune responses in platelets. Hence, anti-platelet drugs have been used to treat patients with infections and inflammation. However, due to the increased risk of bleeding with current anti-platelet drugs, alternative therapeutic targets need to be identified to ameliorate the consequences of inflammation-driven platelet hyperactivation. Previously, we demonstrated that resting platelets exhibit a metabolic plasticity that facilitates fuel selection flexibility, while in contrast, thrombin-stimulated platelets become highly glycolytic. Since multiple aspects of platelet activation require energy in terms of ATP, we investigated metabolic alterations in TLR1/TLR2-activated platelets. In this study, we have demonstrated that TLR1/TLR2-induced platelet activation reprogrammed platelets to upregulate glycolysis via CD36-linked mechanisms. In addition, we showed that this glycolytic flux is controlled by hexokinase (HK), which plays a crucial role in TLR1/TLR2-induced platelet aggregation. Targeting platelet metabolism plasticity may offer a novel strategy to inhibit platelet function in TLR-initiated diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Discovery and Translational Science Department, Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds LS2 9JT, UK.
ORCID-Profile: Lih T Cheah, Mohammad Ali, Cedric Duval, Amanda J Unsworth
Förderung
- British Heart Foundation
Zitieren
APA
Cheah, L. T., Khalil, J. S., McKay, M., Ali, M., Duval, C., Unsworth, A. J., & Naseem, K. M. (2025). Metabolic Reprogramming in Toll-like Receptor-Mediated Platelet Activation. Cells. https://doi.org/10.3390/cells14120906
Vancouver
Cheah LT, Khalil JS, McKay M, Ali M, Duval C, Unsworth AJ, et al. Metabolic Reprogramming in Toll-like Receptor-Mediated Platelet Activation. Cells. 2025. doi:10.3390/cells14120906
BibTeX
@article{Cheah2025,
author = {Cheah, Lih T and Khalil, Jawad S and McKay, Mary and Ali, Mohammad and Duval, Cedric and Unsworth, Amanda J and Naseem, Khalid M},
title = {Metabolic Reprogramming in Toll-like Receptor-Mediated Platelet Activation},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14120906}
}
EUVIMED